Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that Nancy Pecota, Aradigm's Chief Financial Officer, will present an overview of the Company at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York, New York on Wednesday, November 16, 2016 at 1:30 pm Eastern Time. A live webcast of the presentation will be available at www.aradigm.com and a webcast replay will be archived on the Company's website for 30 days. About Aradigm Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm is currently in Phase 3 development of Pulmaquin® (an investigational proprietary formulation of ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis. Aradigm's inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax. More information about Aradigm can be found at www.aradigm.com. Aradigm, Pulmaquin and the Aradigm Logo are registered trademarks of Aradigm Corporation.